SILENCE THER. (SLN)

 

Latest News

Preliminary Results for the year to 31 Dec 2016

RNS Number: 6802A Silence Therapeutics PLC 28 March 2017 Preliminary results for the year to 31 December 2016 28 March 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces its preliminary r...

Notice of Results

RNS Number: 8042Y Silence Therapeutics PLC 08 March 2017 Notice of Results 8 March 2017 London, 8 March 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, plans to announce its Preliminary Result...

Silence update on stake in Arrowhead Pharmaceuticals

Silence Therapeutics has issued an update to its announcement on 9 January regarding the acquisition of a minority stake ...

Minority Stake in Arrowhead Pharmaceuticals

RNS Number: 1602U Silence Therapeutics PLC 13 January 2017 Minority stake in Arrowhead Pharmaceuticals 13 th January 2017 London, 13 th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, p...

All News

DateHeadlineSource
28-03-17Preliminary Results for the year to 31 Dec 2016RNS
08-03-17Notice of ResultsRNS
13-01-17Silence update on stake in Arrowhead PharmaceuticalsStockMarketWire
13-01-17Minority Stake in Arrowhead PharmaceuticalsRNS
09-01-17Silence Therapeutics acquires minority stake in ArrowheadStockMarketWire
09-01-17Acquisition of Minority Stake in ArrowheadRNS
20-12-16Silence Therapeutics notes Quark arbitration resolutionStockMarketWire
20-12-16Silence announces Quark arbitration resolutionRNS
15-11-16CRISPR/Cas9 Gene Editing DataRNS
27-09-16Broker Forecast - Canaccord Genuity issues a broker note on Silence Therapeutics PLCStockMarketWire
27-09-16Silence Therapeutics widens H1 lossStockMarketWire
27-09-16Half-year ReportRNS
22-09-16Notice of ResultsRNS
05-09-16Appointment of CSO and Non-Executive DirectorRNS
18-07-16Director/PDMR ShareholdingRNS
17-06-16Silence resolutions passed at AGMStockMarketWire
17-06-16Result of AGMRNS
01-06-16Holding(s) in CompanyRNS
24-05-16Board Changes, Advisory Board and Notice of AGMRNS
03-05-16Silence Therapeutics Plc to present at the SHARES Investor Evening in London on 19th MayStockMarketWire
19-04-16Director/PDMR ShareholdingRNS
18-04-16Director/PDMR ShareholdingRNS
18-04-16Grant of share options to Chief ExecutiveRNS
05-04-16Should You Dump AstraZeneca plc And Buy BTG plc & Silence Therapeutics plc?Motley Fool
05-04-16SLN updates on Atu027-I-02 studyStockMarketWire
05-04-16Silence Therapeutics narrows FY pretax lossStockMarketWire
05-04-16Atu027 UpdateRNS
05-04-16Final ResultsRNS
30-03-16Holding(s) in CompanyRNS
22-03-16Notice of ResultsRNS
18-01-16Board changesRNS
12-11-15Board appointmentRNS
30-10-15Licensee's drug to commence Ph 2/Ph 3 trialsRNS
29-09-15Interim ResultsRNS
22-09-15Board Change and Notice of ResultsRNS
28-08-15AIM share consolidations: winners and losersInteractive Investor
30-07-15Interim Board ChangeRNS
12-06-15Meet AIM's survivors 20 years onInteractive Investor
01-06-15Result of AGMRNS
01-06-15SLN updates on pancreatic cancer trial interim analysisStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory